Provided by Tiger Trade Technology Pte. Ltd.

Eli Lilly

1,123.00
-1.2100-0.11%
Pre-market: 1,128.045.04+0.45%06:14 EDT
Volume:2.00M
Turnover:2.25B
Market Cap:1.06T
PE:37.70
High:1,133.79
Open:1,126.08
Low:1,120.52
Close:1,124.21
52wk High:1,292.65
52wk Low:712.05
Shares:945.38M
Float Shares:939.00M
Volume Ratio:0.86
T/O Rate:0.21%
Dividend:6.69
Dividend Rate:0.60%
EPS(TTM):29.79
EPS(LYR):22.95
ROE:102.29%
ROA:20.36%
PB:31.34
PE(LYR):48.93

Loading ...

Eli Lilly & Co. Stock Outperforms Competitors on Strong Trading Day

Dow Jones
·
Jul 29

Novo Nordisk Must Face US Shareholder Lawsuit over CagriSema Weight Loss Trial

Reuters
·
Jul 29

Goldman Sachs Forecasts Weak Obesity Pill Sales from Eli Lilly (LLY)

TIPRANKS
·
Jul 28

Analysts Are Bullish on Top Healthcare Stocks: Eli Lilly & Co (LLY), Kyverna Therapeutics, Inc. (KYTX)

TIPRANKS
·
Jul 28

Leah Bennett: Where to Invest After the AI-Chip Stock Surge

Dow Jones
·
Jul 27

Dow Jones Top Company Headlines at 9 PM ET: Nvidia in Talks with Openai to Guarantee $250 Billion Financing for Data Center | Waymo ...

Dow Jones
·
Jul 27

Sector Update: Healthcare

MT Newswires Live
·
Jul 25

Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY) and Atricure (ATRC)

TIPRANKS
·
Jul 24

Novo Nordisk Pursues Injunction to Block Eli Lilly’s (LLY) Advertisements

TIPRANKS
·
Jul 24

As Lilly and Novo Clash in Court, Wall Street is Eyeing This Bigger Prize

Dow Jones
·
Jul 24

Dow Jones Top Company Headlines at 7 am ET: Novo Nordisk Seeks Injunction Against Eli Lilly in Dispute over Weight-loss Ads | EU ...

Dow Jones
·
Jul 24

Novo Nordisk Seeks Preliminary Injunction Against Lilly Weight-loss Ads

Reuters
·
Jul 24

Novo Nordisk: Asked the Court to Preliminarily Halt Eli Lilly's Misleading Glp-1 Advertising Campaigns While Novo Nordisk’s Lawsuit Proceeds

THOMSON REUTERS
·
Jul 24

Lilly Stock is Rising on Plan to Seek Approval for Newest Weight-loss Drug in 2027

Dow Jones
·
Jul 24

Eli Lilly (LLY) Targets 2027 for Approval of Its Next-Generation Obesity Drug

TIPRANKS
·
Jul 23

Eli Lilly's Two Clinical Trials Meet Endpoints, Plans to File Next-Generation Weight Loss Drug by 2027

Deep News
·
Jul 23

Roche Prepares for Windfall from Eli Lilly's Obesity Pill

Dow Jones
·
Jul 23

Pre-Market: Nasdaq Futures Drop 0.83% as Google and Tesla Decline; European Borrowing Costs Surge

Deep News
·
Jul 23

Eli Lilly notes retatrutide met primary endpoint in TRIUMPH-2, TRIUMPH-3 trials

TIPRANKS
·
Jul 23

Lilly Targets Q1 2027 FDA Filing for Retatrutide Obesity Approval

Reuters
·
Jul 23